On June 17, 2025, Zentalis Pharmaceuticals held its Annual Meeting of Stockholders, where 58.9% of shares voted to elect three directors and approve Ernst & Young as auditors for 2025. The named executive officers' compensation was also approved with 29.5 million votes in favor.